EN DE

Airway Medix S.A (AWM) Fair Value & Analysis

Healthcare · PL · Market cap 34.1M PLN

AM Airway Medix S.A AWM · WAR
Price0.2660 PLN
Fair Value0.1190 PLN
Upside-55.3%
Quality14/100
Watch Airway Medix S.A for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Negative equity (buybacks among others) · negative free cash flow
Mixed vs. peers (3/7)
Narrow moat 30/100
Evidence: Medium Range 0.0765 PLN – 0.1615 PLN Share as image

Fair value as of: Jul 19, 2026

From 6 valuation models · updated 22 days ago

Share price +0.6% over the past month.

Below-average quality, and screening another 55% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (0.1615 PLN). The favourable scenario is already priced in.
  • Weak quality (14/100) and above fair value at the same time, the margin of safety is missing on both counts.
  • A fairly wide model range (0.0765 PLN to 0.1615 PLN) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

1.76 PLN 0.2100 PLN Fair Value 0.1190 PLN Apr 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.

How to read this chart

60‑month range 0.2100 PLN – 1.76 PLN · fair‑value band 0.0765 PLN – 0.1615 PLN · the 0.2660 PLN price screens above the 0.1190 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 19, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Airway Medix S.A (AWM) currently trades at 0.2660 PLN, while our model-based Fair Value estimate is 0.1190 PLN, implying the stock looks roughly 55.3% overvalued today. The Quality Score stands at 14/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Trailing-twelve-month revenue stands at 89.0K PLN. Revenue declined 63.6% year over year. It earns a return on equity of 11.3%. Net debt stands at 12.7M PLN. Fundamentals as of Jul 19, 2026

Our scenario range runs from 0.0765 PLN (bear case) to 0.1615 PLN (bull case); at 0.2660 PLN, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 47% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -55%, AWM screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth-Adj P/E 0.4400 PLN 0.6200 PLN 0.8100 PLN 68
P/E Multiple 0.2500 PLN 0.3300 PLN 0.4200 PLN 63
Graham-Dodd 0.1000 PLN 0.7200 PLN 1.01 PLN 54
All 6 models by family
DCF Models
Owner Earnings 0.1600 PLN 0.3000 PLN 0.5600 PLN 31
Earnings-Based
Graham-Dodd 0.1000 PLN 0.7200 PLN 1.01 PLN 54
Lynch FV 0.3200 PLN 0.4600 PLN 0.5900 PLN 50
PEG = 1.0 0.3200 PLN 0.4600 PLN 0.5900 PLN 46
Multiples
P/E Multiple 0.2500 PLN 0.3300 PLN 0.4200 PLN 63
Growth Earnings
Growth-Adj P/E 0.4400 PLN 0.6200 PLN 0.8100 PLN 68

Widest divergence: Growth Earnings (0.6200 PLN) versus DCF Models (0.3000 PLN). Highest evidence: Growth-Adj P/E (68).

Notify me when AWM reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 89.0K PLN
Revenue growth (YoY) -63.6%
Net margin 1,437%
Return on equity 11.3%
Free cash flow −3.6M PLN FY2025
P/E ratio 13.7
More key figures
Operating margin -1,006%
EPS (TTM) 0.0200 PLN
Net debt 12.7M PLN FY2025

Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 14/100

Of which business quality 17 · Market factors (momentum, volatility) 29

Profitability 46
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 2
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 67
Calm price path (market factor)
Momentum 18
Price trend over the last 3–12 months (market factor)
52W Momentum 6
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Airway Medix S.A. engages in the research, development, and commercialization of medical devices for the mechanically ventilated patients in the intensive care units and for the patients in life-threatening conditions in the anaesthesiology departments in Poland and internationally.

Full company description

Airway Medix S.A. engages in the research, development, and commercialization of medical devices for the mechanically ventilated patients in the intensive care units and for the patients in life-threatening conditions in the anaesthesiology departments in Poland and internationally. It offers Closed Suction System, a dual operation of balloon swiping and suction; B-Oral Care for intubated hospital patients; Hyper Form, a ventilation laryngeal masks and tube cuffs; and Cuff Pressure Regulator, single-patient use device that provides continuous regulation of pressure in inflatable ventilation tube cuffs. Airway Medix S.A. was founded in 2010 and is based in Warsaw, Poland.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Airway Medix S.A reported revenue of 4.0K PLN in FY2025 versus 6.0K PLN in FY2021, a compound −9.6%/yr. Reported net income was 1.7M PLN in FY2025.

Growth Quality 5/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
4.0K PLN
Latest YoY
−66.7%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−65.2%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−56.5%
Avg. growth/yr (9Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−25.6%
Revenue −9.6%/yr
FY21 6.0K PLN
FY22 95.0K PLN
FY23 12.0K PLN
FY24 12.0K PLN
FY25 4.0K PLN
Net income
FY21 −7.0M PLN
FY22 −37.9M PLN
FY23 −3.3M PLN
FY24 −11.7M PLN
FY25 1.7M PLN

AWM screens 55% overvalued. Compare with Intuitive Surgical, Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Airway Medix S.A Fair Value". https://www.fairvalue-calculator.com/stock/AWM

Peer Group

Medical Instruments & Supplies · 203 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 14 · Bottom 25%
Fair Value upside −55% · Below median
Return on equity (TTM) 11% · Above median
Return on assets -56% · Bottom 25%
Revenue growth -64% · Bottom 25%

Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 14.8× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 0
FUTURE 0 · sector 27
PAST 45 · sector 25
HEALTH 100 · sector 96
DIVIDEND 0 · sector 32

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $402.33 $150.04 -63%
EssilorLuxottica Société anonyme 1EL €172.45 €68.55 -60%
Medline Inc MDLN $41.11 $30.15 -27%
Becton, Dickinson and Company BDX $150.65 $103.53 -31%
Alcon Inc ALC $70.26 $39.78 -43%
ResMed Inc RMD $203.87 $187.89 -8%
West Pharmaceutical Services, Inc WST $353.71 $143.97 -59%
Straumann Holding STMN CHF 106.00 CHF 47.31 -55%
Sartorius Stedim Biotech S.A DIM €188.50 €51.16 -73%
Coloplast A/S COLOB kr 414.00 kr 382.22 -8%

Compare Airway Medix S.A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Airway Medix S.A (AWM) overvalued or undervalued?
As of Jul 19, 2026, our model estimates a fair value of 0.1190 PLN versus a price of 0.2660 PLN, about −55% (overvalued).
What is the fair value of AWM?
Our model-based fair value for Airway Medix S.A is 0.1190 PLN (as of Jul 19, 2026), built from audited fundamentals. The current price is 0.2660 PLN.
What is the quality score of AWM?
Airway Medix S.A has a Quality Score of 14/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Airway Medix S.A (AWM)?
Airway Medix S.A reported trailing-twelve-month revenue of about 89.0K PLN (latest available figure, as of Jul 19, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Airway Medix S.A and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.